By Application
Hot products 
-
Mouse Anti-ENO1 Recombinant Antibody (8G8) (CBMAB-E1329-FY)
-
Mouse Anti-APOH Recombinant Antibody (4D9A4) (CBMAB-A3249-YC)
-
Mouse Anti-Acetyl-α-Tubulin (Lys40) Recombinant Antibody (V2-623485) (CBMAB-CP2897-LY)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-DISP2 Monoclonal Antibody (F66A4B1) (CBMAB-1112CQ)
-
Mouse Anti-ADGRL2 Recombinant Antibody (V2-58519) (CBMAB-L0166-YJ)
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-C5AR1 Recombinant Antibody (R63) (CBMAB-C9553-LY)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
-
Mouse Anti-AMH Recombinant Antibody (5/6) (CBMAB-A2527-YC)
-
Mouse Anti-BAD (Phospho-Ser136) Recombinant Antibody (CBYY-0138) (CBMAB-0139-YY)
-
Mouse Anti-FLT1 Recombinant Antibody (11) (CBMAB-V0154-LY)
-
Mouse Anti-CD24 Recombinant Antibody (HIS50) (CBMAB-C10123-LY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Mouse Anti-GFAP Recombinant Antibody (5) (CBMAB-G0346-LY)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
Carcinoid
Fig.1 Carcinoid
Carcinoid (also carcinoid tumor) is a slow-growing type of neuroendocrine tumor developing from the cells of the neuroendocrine system. The tumors of the midgut (jejunum, ileum, cecum and appendix) are related to carcinoid syndrome. Carcinoid tumors overwhelmingly show as malignant tumor of the appendix, but they are most commonly related to the small intestine, and they can also be found in the stomach and rectum. They are considered to grow in the liver, but this finding is normally a display of metastatic disease from a primary carcinoid occurring somewhere in the body. They have a very mind growth rate compared to most malignant tumors. The median age at diagnosis for all patients with neuroendocrine tumors is 63 years. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with MRI or CT, labs for tumor markers such as serotonin can be applied.
Loading...
Compare
